Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
[ad_1]
Recently co-authored a retrospective study of nearly 16,000 patients with diabetic macular edema (DME), a common cause of visual impairment:
At 1 year, despite treatment, real-world DME patients have meaningfully worse visual outcomes compared to patients in randomized controlled trials, and those with well-preserved baseline vision are particularly prone to vision loss.
https://www.sciencedirect.com/science/article/abs/pii/S2468653018302653
This study assessed real-world visual acuity (VA) outcomes of anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (…
[ad_2]
Return to main website.